Over 66% of US citizens over 12 are eligible for monoclonal antibodies when they test positive for Covid-19 or are exposed to someone who tests positive, assuming they don’t wait till they are seriously ill.
Here is detailed information of eligibility. You are eligible if you are over 64 or overweight or obese or have high blood pressure or...
Monoclonal antibodies are quite effective at preventing hospitalizations and deaths.
Monoclonal antibodies are free, but some clinics charge for administration.
Are you planning to get monoclonal antibody treatment if you test positive?
Why not?
The death rate is lower among the vaccinated and boosted, but it is not that much lower.
Your decision to not get monoclonal antibodies could kill you.
Tuesday, Dec 21, 2021 · 12:28:16 PM +00:00
·
tadamsmar
Just want to mention an error I made in a number of replies. I implied that the clock starts ticking on monoclonal antibodies (mAb) when you get a positive test. The clock starts when you show symptoms. So, to optimize your chances you need to get tested promptly if you have symptoms and contact your doctor promptly anyone in your home tests positive. (Also it might be good to be aware of all your risk factors and remind your doctor of all of them.)
The information I find indicates that you should get mAb ASAP and the clock runs out 10 days after the onset of symptoms. But don’t take 10 days as gospel, policies and circumstances vary, so it could be shorter or longer.
Tuesday, Dec 21, 2021 · 2:11:23 PM +00:00
·
tadamsmar
Some strongly questioned my characterization of the death rates so I am providing some facts and you can decide for yourself.
For the general population the death rate per 500 among those testing positive is ~6.5 for the unvaccinated, ~2 for the vaccinated, and ~1 for the boosted.
I don’t have the data for the high risk group within the general population.
And note that the hospitalization rates vary widely for breakthrough infections depending on the number of comorbidities that you have. There is a higher risk subgroup among the high risk group that qualifies for mAb under the federal guidelines.